Clinical trials: Thalidomide
Multiple Myeloma
Escalating Doses of Thalidomide in Conjunction With Bortezomib and HIgh Dose Melphalan for BSCT
The primary objective of this study is to: Determine the maximum tolerated dose of thalidomide used in conjunction with dose-intense melphalan, bortezomib and autologous (syngeneic) HSC support in the salvage therapy of patients…
- Trial name
- Thal/Mel/Vel (NCT01242267)
- Testing
- Thalidomide+Melphalan +Bortezomib+stem cell transplant
- Where
- United States
- Volunteers
- 29 people
- Sponsor
- Hackensack Meridian Health
Radiation Enteritis
Efficacy and Safety of Thalidomide Combined With Glutamine in the Treatment of Radiation Intestinal Injury.
At present, there is still a lack of standard and effective treatment strategies and procedures for radiation intestinal injury.
- Trial name
- NCT06617182
- Testing
- Thalidomide, Glutamine, Thalidomide+Glutamine
- Where
- China
- Volunteers
- 150 people
- Sponsor
- Yongquan Shi
Periodic Fever, Aphthous Stomatitis, Pharyngitis, and Adenitis Syndrome
Efficacy and Safety of Thalidomide for Pediatric PFAPA Syndrome
The goal of this clinical trial is to evaluate the efficacy and safety of thalidomide in the treatment of children with Periodic Fever, Aphthous Stomatitis, Pharyngitis, and Adenitis (PFAPA) syndrome.
- Trial name
- NCT07476625
- Testing
- Thalidomide (50mg), Colchicine
- Volunteers
- 106 people
- Sponsor
- Wenjie Zheng
Waldenström Macroglobulinemia
The Efficacy of TCD Following by TP Maintenance Therapy in Newly Diagnosed WM
The purpose of this study is to evaluate the efficiency of an oral regimen in newly diagnosed Waldenström macroglobulinemia: thalidomide plus cyclophosphamide and dexamethasone following by thalidomide and prednisone maintenance…
- Trial name
- BDH-WM02 (NCT02844309)
- Testing
- Thalidomide
- Where
- China
- Volunteers
- 44 people
- Sponsor
- Institute of Hematology & Blood Diseases Hospital, China
Mantle Cell Lymphoma
EDOCH Alternating With DHAP for New Diagnosed Younger MCL
The purpose of this study is to: 1. determine the efficiency of EDOCH (etoposide,dexamethasone,doxorubicin, cyclophosphamide and vincristine) alternating with DHAP (cisplatin, cytarabine and dexamethasone) regimen combined with…
- Trial name
- BDH-MCL01 (NCT02858804)
- Testing
- Etoposide, Doxorubicin, Dexamethasone
- Where
- China
- Volunteers
- 55 people
- Sponsor
- Institute of Hematology & Blood Diseases Hospital, China
Multiple Myeloma
UARK 2006-66, Total Therapy 3B: An Extension of UARK 2003-33 Total Therapy
With this study - Total Therapy IIIB - researchers are extending the findings of Total Therapy III based what they have learned from the first two studies (Total Therapy I and II), with new research strategies designed to explore…
- Trial name
- NCT00572169
- Testing
- Velcade, Thalidomide, Dexamethasone
- Where
- United States
- Volunteers
- 177 people
- Sponsor
- University of Arkansas
Transfusion-dependent β-thalassemia Patients
Evaluating the Clinical Efficacy and Safety of Luspatercept Combined With Thalidomide in the Treatment of β-TDT Patients
β-thalassemia is one of the most common inherited hemoglobinopathies worldwide and a major public health issue that severely impacts birth quality, human health, and social progress.
- Trial name
- NCT07338344
- Testing
- Luspatercept combined with low-dose thalidomide
- Where
- 8 sites in China
- Volunteers
- 78 people
- Sponsor
- Rongrong Liu
Hepatocellular Cancer (HCC)
Effect of TCC Cocktail Combined With TACE Versus TACE Alone on Survival in uHCC Patients
This is a multicenter, retrospective cohort study that aims to evaluate the efficacy and safety of a triple-drug cocktail (TCC), consisting of Thalidomide, Carmofur, and Compound Mylabris Capsules (CMC), in combination with…
- Trial name
- NCT07321613
- Testing
- Thalidomide (50mg), carmofur, compound mylabris capsule
- Where
- China
- Volunteers
- 545 people
- Sponsor
- Shanghai Zhongshan Hospital
Hepatocellular Carcinoma
A Phase III Randomized Study of TACE Plus an Oral Triple-Agent Cocktail Versus TACE Plus First-Line Targeted Immunotherapy in Unresectable Hepatocellular Carcinoma
This is a prospective, multicenter, randomized, open-label phase 3 study evaluating the efficacy and safety of transarterial chemoembolization (TACE) combined with a triple oral cocktail regimen versus TACE combined with targeted…
- Trial name
- Cocktail-001 (NCT07309419)
- Testing
- Apatinib, Camrelizumab, TACE
- Volunteers
- 222 people
- Sponsor
- Shanghai Zhongshan Hospital
T-LGL Leukemia, NK-LGL Leukemia
Thalidomide for the Symptomatic Large Granular Lymphocytic Leukemia
There is currently no standard first-line treatment for LGLL. The investigators used the TPM regimen (thalidomide + prednison + methotrexate ) to treat LGLL since 2020, enrolling a total of 54 patients and achieving an overall…
- Trial name
- NCT06530576
- Testing
- Thalidomide and methotrexate
- Where
- China
- Volunteers
- 48 people
- Sponsor
- Institute of Hematology & Blood Diseases Hospital, China
Langerhans Cell Histiocytosis (LCH)
Efficacy and Safety of XTD Regimen (Selinexor, Thalidomide and Dexamethasone) in Adult Patients With Relapsed/Refractory LCH
In adult patients with relapsed/refractory Langerhans cell histiocytosis (LCH), a treatment regimen of XTD regimen (Selinexor, Thalidomide and Dexamethasone) is planned to be used.
- Trial name
- NCT07204041
- Testing
- Selinexor, Thalidomide (100mg), Dexamethasone
- Where
- China
- Volunteers
- 40 people
- Sponsor
- Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Non Neoplastic Condition, Precancerous Condition
Thalidomide in Treating Patients With Relapsed or Progressive Systemic Mastocytosis
RATIONALE: Thalidomide may stop the growth of systemic mastocytosis by blocking blood flow to the disease. PURPOSE: This phase II trial is studying how well thalidomide works in treating patients with relapsed or progressive…
- Trial name
- NCT00769587
- Testing
- thalidomide
- Where
- France
- Sponsor
- Centre Hospitalier Universitaire, Amiens
Langerhans Cell Histiocytosis
Efficacy and Safety of Low-Dose Cytarabine Combined With Thalidomide in Adult Patients With Untreated LCH
Treatment of Adult Patients with Newly Diagnosed Langerhans Cell Histiocytosis (LCH) Using a Low-Dose Cytarabine Combined with Thalidomide Regimen.
- Trial name
- NCT07187193
- Testing
- Cytarabine (Ara-C), Thalidomide (100mg)
- Where
- China
- Volunteers
- 50 people
- Sponsor
- Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Germ Cell Tumor, Yolk Sac Tumor
Thalidomide Combined With Chemotherapy in the Treatment of Relapsed or Refractory Yolk Sac Tumor
Remarkable progress has been made in treating germ-cell tumor (GCT) through the use of platinum-based regimens. However, part of yolk sac tumor (YST) with cisplatin resistance or recurrence is nevertheless prone to relapse after…
- Trial name
- NCT06470464
- Testing
- Thalidomide combined with TGA chemotherapy (nab-paclitaxel + gemcitabine+ epirubicin)
- Where
- China
- Volunteers
- 20 people
- Sponsor
- Shandong First Medical University
Relapsed or Refractory Systemic Light Chain Amyloidosis
Study of Dexamethasone Plus IXAZOMIB (MLN9708) or Physicians Choice of Treatment in Relapsed or Refractory Systemic Light Chain (AL) Amyloidosis
The purpose of this study is to provide continued access of ixazomib and/or other study medications and to continue collecting relevant safety data to monitor participant's safety, determine whether dexamethasone plus IXAZOMIB…
- Trial name
- NCT01659658
- Testing
- IXAZOMIB, Dexamethasone, Melphalan
- Where
- 66 sites in United States, Australia and 13 more
- Volunteers
- 177 people
- Sponsor
- Millennium Pharmaceuticals, Inc.
Extramedullary Multiple Myeloma
Aponermin-Based Bridging Therapy Prior to CAR-T Infusion in Relapsed/Refractory Multiple Myeloma Patients With Extramedullary Disease
This is a prospective, single-arm, multicenter, open-label study to evaluate the efficacy and safety of aponermin-based bridging therapy prior to CAR-T infusion in relapsed/refractory multiple myeloma patients with extramedullary…
- Trial name
- NCT06793475
- Testing
- anti-BCMA/GPRC5D bispecific CAR-T, Apornemin, Carfilzomib
- Where
- 2 sites in China
- Volunteers
- 20 people
- Sponsor
- Institute of Hematology & Blood Diseases Hospital, China
Thalidomide Enhances Clinical Efficacy of Cetuximab Combined With Standard Chemotherapy for Left Colorectal Cancer
Thalidomide Enhances Clinical Efficacy of Cetuximab Combined With Standard Chemotherapy for Left Colorectal Cancer
1. To verify that thalidomide can increase the efficacy of cetuximab plus chemotherapy in the treatment of stage IV RAS and BRAF wild-type unresectable left colorectal cancer, which has important clinical significance and…
- Trial name
- NCT06279351
- Testing
- Thalidomide+cetuximab+FOLFOX/FOLFIRI
- Where
- China
- Volunteers
- 96 people
- Sponsor
- Xinqiao Hospital of Chongqing
Fetal Hemoglobin, Beta-Thalassemia
Long Term Beta Thalassemia Treatment: Findings From The Extension Period
The project, titled "Long Term Beta Thalassemia Treatment: Findings From The Extension Period Of Phase 2 Clinical Trial," aims to compare the efficacy and safety of combination therapy (thalidomide and hydroxyurea) versus…
- Conditions
- Fetal Hemoglobin, Beta-Thalassemia, Hemoglobinopathies
- Trial name
- Thalidomide (NCT06490601)
- Testing
- thalidomide and hydroxyurea, Thalidomide
- Where
- Pakistan
- Volunteers
- 30 people
- Sponsor
- National Institute of Blood and Marrow Transplant (NIBMT), Pakistan
Fetal Hemoglobin, Thalassemia Major
Unraveling the Impact of Thalidomide at Diverse Doses in Transfusion Dependent Beta Thalassemia
The project "Unraveling the Impact of Thalidomide at Diverse Doses in Transfusion Dependent Beta Thalassemia" investigates the safety and efficacy of low-dose thalidomide in managing beta thalassemia, a genetic disorder causing…
- Conditions
- Fetal Hemoglobin, Thalassemia Major, Genetic Disease
- Trial name
- BTM (NCT06490627)
- Testing
- Thalidomide
- Where
- Pakistan
- Volunteers
- 54 people
- Sponsor
- National Institute of Blood and Marrow Transplant (NIBMT), Pakistan
Inflammatory Bowel Diseases
Thalidomide Therapy for VEOIBD
This is a single center, observational study to investigate the clinical outcomes of thalidomide treatment for very early onset inflammatory bowel disease
- Trial name
- NCT06382519
- Testing
- Thalidomide
- Where
- China
- Volunteers
- 40 people
- Sponsor
- Children's Hospital of Fudan University